SCHEMBL4744573

SCHEMBL4744573

CSc1nc(-c2cccs2)nc(NN)c1C#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 6/20 0.49
MAPT P10636 6/20 0.49
HPGD P15428 4/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FLT3 P36888 1/20 0.46
NPSR1 Q6W5P4 4/20 0.44
PRNP P04156 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8384543 0.79 NPSR1 (0.53) ALDH1A1KDM4EMAPTHPGDLMNA
SCHEMBL7892150 0.78 FLT3 (0.46) CYP1A2CYP2C19CYP3A4CYP2C9ALDH1A1
SCHEMBL8378163 0.77 RELA (0.66) FLT3
SCHEMBL4747831 0.74 NPSR1 (0.51) ALDH1A1KDM4EMAPTHPGDLMNA
SCHEMBL6442951 0.74 KDM4E (0.68) CYP1A2CYP2C19CYP3A4CYP2C9ALDH1A1
SCHEMBL8383001 0.73 NPSR1 (0.44) CYP1A2CYP2C19CYP3A4CYP2C9ALDH1A1
SCHEMBL6440764 0.73 CYP1A2 (1.00) CYP1A2CYP2C19CYP3A4CYP2C9ALDH1A1
SCHEMBL4744572 0.72 MAPT (0.55) ALDH1A1KDM4EMAPTHPGDNPSR1
SCHEMBL8398932 0.71 FOS (0.57) CYP1A2CYP3A4ALDH1A1KDM4EMAPT
SCHEMBL967859 0.70 ALDH1A1 (0.47) CYP1A2CYP2C19CYP3A4CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO claimed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US claimed
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221103-A1 New heterocyclic compounds LOXL4, CXCR4, LTC4S CYP1A2 448/4885CYP2C19 1313/4885CYP3A4 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.